138 related articles for article (PubMed ID: 26749158)
21. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial.
Lucas GM; Chaudhry A; Hsu J; Woodson T; Lau B; Olsen Y; Keruly JC; Fiellin DA; Finkelstein R; Barditch-Crovo P; Cook K; Moore RD
Ann Intern Med; 2010 Jun; 152(11):704-11. PubMed ID: 20513828
[TBL] [Abstract][Full Text] [Related]
22. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.
Fiellin DA; Pantalon MV; Chawarski MC; Moore BA; Sullivan LE; O'Connor PG; Schottenfeld RS
N Engl J Med; 2006 Jul; 355(4):365-74. PubMed ID: 16870915
[TBL] [Abstract][Full Text] [Related]
23. Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth.
Subramaniam GA; Warden D; Minhajuddin A; Fishman MJ; Stitzer ML; Adinoff B; Trivedi M; Weiss R; Potter J; Poole SA; Woody GE
J Am Acad Child Adolesc Psychiatry; 2011 Nov; 50(11):1120-8. PubMed ID: 22024000
[TBL] [Abstract][Full Text] [Related]
24. Therapy Dose Mediates the Relationship Between Buprenorphine/Naloxone and Opioid Treatment Outcomes in Youth Receiving Medication for Opioid Use Disorder Treatment.
Hammond CJ; Kady A; Park G; Vidal C; Wenzel K; Fishman M
J Addict Med; 2022 Mar-Apr 01; 16(2):e97-e104. PubMed ID: 33973923
[TBL] [Abstract][Full Text] [Related]
25. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.
Parran TV; Adelman CA; Merkin B; Pagano ME; Defranco R; Ionescu RA; Mace AG
Drug Alcohol Depend; 2010 Jan; 106(1):56-60. PubMed ID: 19717249
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
[TBL] [Abstract][Full Text] [Related]
27. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
Rhee TG; Rosenheck RA
Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
[TBL] [Abstract][Full Text] [Related]
28. The More Things Change: Buprenorphine/naloxone Diversion Continues While Treatment Remains Inaccessible.
Carroll JJ; Rich JD; Green TC
J Addict Med; 2018; 12(6):459-465. PubMed ID: 30095563
[TBL] [Abstract][Full Text] [Related]
29. Buprenorphine Induction in Persons With Opioid Use Disorder Hospitalized with Acute Hepatitis A.
Oller DA; Thornton C; Nuzzo PA; Fanucchi LC
J Addict Med; 2021 May-Jun 01; 15(3):187-190. PubMed ID: 32909986
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of incentivised adherence and abstinence monitoring in buprenorphine maintenance: a pragmatic, randomised controlled trial.
Elarabi HF; Shawky M; Mustafa N; Radwan D; Elarasheed A; Yousif Ali A; Osman M; Kashmar A; Al Kathiri H; Gawad T; Kodera A; Al Jneibi M; Adem A; Lee AJ; Marsden J
Addiction; 2021 Sep; 116(9):2398-2408. PubMed ID: 33404141
[TBL] [Abstract][Full Text] [Related]
31. A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxone.
Blum K; Han D; Modestino EJ; Saunders S; Roy AK; Jacobs W; Inaba DS; Baron D; Oscar-Berman M; Hauser M; Badgaiyan RD; Smith DE; Femino J; Gold MS
Subst Use Misuse; 2018 Jan; 53(2):220-229. PubMed ID: 29257919
[TBL] [Abstract][Full Text] [Related]
32. Buprenorphine/naloxone treatment practices in Malaysia: Results of national surveys of physicians and patients.
Vicknasingam B; Dazali MN; Singh D; Schottenfeld RS; Chawarski MC
Drug Alcohol Depend; 2015 Jul; 152():164-9. PubMed ID: 25935736
[TBL] [Abstract][Full Text] [Related]
33. Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth.
Warden D; Subramaniam GA; Carmody T; Woody GE; Minhajuddin A; Poole SA; Potter J; Fishman M; Bogenschutz M; Patkar A; Trivedi MH
Addict Behav; 2012 Sep; 37(9):1046-53. PubMed ID: 22626890
[TBL] [Abstract][Full Text] [Related]
34. Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories.
Jacobs P; Ang A; Hillhouse MP; Saxon AJ; Nielsen S; Wakim PG; Mai BE; Mooney LJ; S Potter J; Blaine JD
Am J Addict; 2015 Oct; 24(7):667-75. PubMed ID: 26400835
[TBL] [Abstract][Full Text] [Related]
35. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States.
Parish WJ; Mark TL; Zarkin GA; Weber E
Addiction; 2022 Jan; 117(1):141-150. PubMed ID: 34033177
[TBL] [Abstract][Full Text] [Related]
36. Sex-based differences in psychiatric symptoms and opioid abstinence during buprenorphine/naloxone treatment in adolescents with opioid use disorders.
Hammond CJ; Park G; Kady A; Rathod K; Rahman N; Vidal C; Wenzel K; Fishman M
J Subst Abuse Treat; 2022 Feb; 133():108495. PubMed ID: 34218992
[TBL] [Abstract][Full Text] [Related]
37. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine.
Korthuis PT; Fiellin DA; Fu R; Lum PJ; Altice FL; Sohler N; Tozzi MJ; Asch SM; Botsko M; Fishl M; Flanigan TP; Boverman J; McCarty D;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S83-90. PubMed ID: 21317600
[TBL] [Abstract][Full Text] [Related]
38. Outcomes associated with once-daily versus multiple-daily dosing of buprenorphine/naloxone for opioid use disorder.
Allen SM; Nichols TA; Fawcett J; Lin S
Am J Addict; 2022 May; 31(3):173-179. PubMed ID: 35226393
[TBL] [Abstract][Full Text] [Related]
39. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder.
Evans EA; Zhu Y; Yoo C; Huang D; Hser YI
Addiction; 2019 Aug; 114(8):1396-1404. PubMed ID: 30916463
[TBL] [Abstract][Full Text] [Related]
40. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
Worley MJ; Heinzerling KG; Shoptaw S; Ling W
Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
